KRAS and non-small cell lung carcinoma: For instance, reduced TTF-1 expression, readily assessable by routine immunohistochemistry, is now recognized as a putative negative prognostic biomarker in KRAS G12C-mutant NSCLC treated with sotorasib [29,125].